February 2018
Pentetrazol for Idiopathic Hypersomnia and Narcolepsy Type 2
Pentetrazol is a medicinal product that is being developed for the treatment of IH and narcolepsy type 2. Pentetrazol is administered orally and it acts by blocking the effect of a chemical substance called Gamma-Aminobutyric Acid (GABA). GABA is thought to play a role in promoting sleeping and is believed to be elevated in people with IH. If licensed, Pentetrazol will offer a new treatment option for patients with IH or narcolepsy type 2.
January 2018
Perampanel (Fycompa) for Paediatric Epilepsy
Epilepsy is a condition in which the brain is affected by abnormal discharge of electrical activity, causing seizures (fits). There are several different types of epileptic seizures, depending on what part of the brain they start in and which part they affect. Epilepsy can start in any age, but is most common in either childhood …
January 2018
PXT3003 for Charcot-Marie-Tooth Disease Type 1A
Charcot-Marie-Tooth disease type 1A (CMT1A) is an inherited genetic disease in which the motor and/or sensory peripheral nerves are affected, resulting in muscle weakness and wasting, as well as sensory loss.
January 2018
Ronopterin for Moderate to Severe Traumatic Brain Injury
Ronopterin is being developed as a continuous infusion that can be used individually or in combination with the current standard treatments for traumatic brain injury. The current medications available are only used to treat the symptoms of traumatic brain injury.
